Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes.

Progress in Cardiovascular Diseases
Vinay GargKim Connelly

Abstract

The treatment landscape for patients with established or at high risk for cardiovascular disease and type 2 diabetes mellitus has entirely changed over the past decade, with the introduction of several anti-hyperglycemic agents. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) agonists are two anti-hyperglycemic classes which have been of special interest after multiple large cardiovascular disease (CVD) outcomes studies have demonstrated superiority of these agents compared to placebo for major adverse CVD events and in some cases, hospitalization for heart failure. Despite the dramatic results of these trials, only recently have we began to understand the mechanisms underlying these CVD benefits. Here we review the underlying mechanisms which have the greatest plausibility for both of these agents including the impact of ventricular loading conditions, direct effects on cardiac structure and function, myocardial energetics and sodium/hydrogen exchange for SGLT2 inhibitors, and the anti-atherosclerotic, anti-inflammatory, and modulation of endothelial function for GLP-1 agonists.

Citations

May 22, 2020·Circulation Research·Marie-Eve PichéJean-Pierre Després
Jun 23, 2020·Obesity·Salvatore CarboneCarl J Lavie
Mar 10, 2020·Canadian Journal of Physiology and Pharmacology·Chris R TriggleMorley D Hollenberg
Jun 18, 2020·Expert Review of Cardiovascular Therapy·Sara SotirakosRichard Armstrong
Jul 1, 2020·Journal of Cardiopulmonary Rehabilitation and Prevention·Barry A FranklinLeonard A Kaminsky
Mar 29, 2020·JAMA : the Journal of the American Medical Association·Mark C PetrieJohn J V McMurray
Oct 6, 2020·Future Cardiology·Sara Sotirakos
Jan 29, 2021·International Journal of Molecular Sciences·Nguyen Ngoc TrangYi-Jen Chen
Nov 6, 2020·Heart Failure Reviews·Mieczysław DutkaMichał Ćwiertnia
Mar 15, 2021·Progress in Cardiovascular Diseases·Carl J Lavie
Apr 7, 2021·British Journal of Pharmacology·Neil TandayNigel Irwin
Aug 21, 2021·Progress in Cardiovascular Diseases·Carl J Lavie
Oct 27, 2020·Journal of the American Association of Nurse Practitioners·Dawn M Battise, Jacqueline L Olin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.